treprostinil
AssetAlso RIN-PF-302, L606, 15-AU-81, L-606
Activates prostanoid receptors to dilate pulmonary arteries and inhibit platelet aggregation.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- PTGIR
- 4
- Indications
- 2
- Trials
- 2
- Developers
Indications
4Idiopathic pulmonary fibrosis
Phase 3, Enrolling by invitation, NCT04905693, clinicaltrials.gov, 7 Oct 2026
Interstitial lung disease
Phase 3, Enrolling by invitation, NCT04905693, clinicaltrials.gov, 7 Oct 2026
Progressive pulmonary fibrosis
Phase 3, Enrolling by invitation, NCT04905693, clinicaltrials.gov, 7 Oct 2026
1 more
In the full profile
- Targets and what it contains3
- Owner and partners2
- Trials2
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.